After entering the capital market, Baiyang Pharmaceuticals, as a leading health brand commercialization platform for A-shares, has further enhanced its ability in brand cultivation and incubation and the convergence of innovative resources, helping to enhance the ecological innovation vitality of urban industries

"New species" triggers changes in Qingdao's pharmaceutical and health industry

Recently, Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Baiyang Pharmaceutical") launched a cosmetic efficacy liability insurance for a functional cosmetic on a commercial platform-if consumers follow the guidelines, if their skin problems are not improved, The claim can be triggered.

Behind Baiyang Pharmaceutical's bold test of cosmetics efficacy liability insurance is its important attempt to accelerate business expansion and enhance platform capabilities as a leading health brand commercialization platform in A-shares. In recent years, Baiyang Pharmaceutical has aimed at the general trend of reform in the pharmaceutical and health industry, relying on more than ten years of experience in the industry to create a new species of health brand commercialization platform. On June 30, Baiyang Pharmaceutical officially listed on the Growth Enterprise Market. Taking this as a node, Baiyang Health brand commercialization platform has entered a new period of rapid development. This also means that the platform's ability in brand cultivation and incubation and the convergence of innovative resources will be further enhanced.

This is not only good for the development of Baiyang Pharmaceutical and its parent company, Baiyang Pharmaceutical Group. As a "new species", the way and level of impact of commercial platforms on urban industries is bound to be different from traditional enterprises. This is undoubtedly an important benefit for Qingdao's pharmaceutical and healthcare industry, which has been seeking to catch up with iteratively in recent years.